Education
About Us
Working with TipRanks
Follow Us
Renalytix (RNLXY)
OTHER OTC:RNLXY
Top Page
No summary available
Positive Factors
Innovative Product Offering
Renalytix's use of machine learning in diagnostics positions it as a leader in innovative kidney disease management, potentially driving long-term growth.
Strategic Partnerships
Strategic collaborations expand market reach and enhance technology adoption, providing diversified revenue streams and long-term business stability.
Revenue Model
The recurring revenue model from testing fees ensures a steady income stream, supporting financial sustainability and growth potential.
Negative Factors
Financial Distress
Ongoing financial distress with negative equity and losses threatens long-term viability, requiring urgent strategic restructuring for recovery.
Negative Cash Flow
Negative cash flow indicates liquidity issues, limiting operational flexibility and the ability to invest in growth opportunities, impacting long-term prospects.
Declining Revenue
Consistent revenue decline reflects challenges in market penetration and product adoption, posing risks to sustainable growth and profitability.
Renalytix (RNLXY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.09M
Dividend YieldN/A
Average Volume (3M)2.45K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth-2.10%
EPS Growth60.11%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryHealthcare Providers & Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,740,374
10 Day Avg. Volume4,700
30 Day Avg. Volume2,446
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Renalytix Business Overview & Revenue Model
Company DescriptionRenalytix AI PLC is a developer of artificial intelligence-enabled clinical decision support solutions for kidney disease and costly chronic medical conditions globally. The company's solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery.
How the Company Makes MoneyRenalytix generates revenue primarily through the sale of its diagnostic products and services to healthcare providers, hospitals, and clinical laboratories. The company's flagship product, KidneyIntelX, is a diagnostic platform that uses machine learning algorithms to assess the risk of kidney disease progression in patients. Revenue is derived from testing fees charged for each use of the KidneyIntelX platform. Additionally, Renalytix engages in partnerships with pharmaceutical companies and healthcare organizations to leverage its technology in drug development and clinical trials, which provides additional revenue streams. Strategic collaborations and licensing agreements also contribute to the company's financial performance, supporting the broader adoption of its diagnostic solutions.
Renalytix Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Renalytix Technical Analysis
―
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNLXY, the sentiment is undefined. The current price of undefined is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for RNLXY.
Renalytix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―